NCT02824003View on ClinicalTrials.gov

Study to Evaluate the Effect of ISIS GCGRRx on Hepatic Lipid and Glycogen Content in Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

December 15, 2016

Study Completion Date

May 22, 2017

Conditions
Type 2 Diabetes
Interventions
DRUG

ISIS-GCGRRx

once weekly dosing for 13 weeks

DRUG

Placebo

once weekly dosing for 13 weeks

Trial Locations (1)

A-1130

Ionis Investigator Site, Vienna

Sponsors
All Listed Sponsors
lead

Ionis Pharmaceuticals, Inc.

INDUSTRY